Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 2nd, 2026

LECO_Weekly-Healthcare-News_3-2-2026Download
  1. IQVIA (NYSE: IQV) Expands Early-Stage Drug Discovery Capabilities with Acquisition of Charles River Discovery Assets IQVIA Holdings Inc. (NYSE: IQV) announced an agreement to acquire select discovery services assets from Charles River Laboratories, strengthening its early-stage R&D capabilities. The assets include five sites offering in vitro drug discovery, AI-driven small molecule platforms, and advanced non-animal research methods backed by over 20 years of scientific data. These capabilities will enhance IQVIA’s integrated platform across drug discovery, from target identification to early safety assessment, covering key therapeutic areas like oncology, neurology, and immunology. The move positions IQVIA to support clients earlier in the drug development lifecycle. The transaction is expected to close in Q2 2026. (Link)
  2. GSK (NYSE: GSK) Agrees to Acquire 35Pharma for $950 Million to Bolster Cardiopulmonary Pipeline GSK announced an agreement to acquire 35Pharma Inc., a Canada-based clinical-stage biopharma company focused on novel protein-based therapeutics. The deal gives GSK full ownership of 35Pharma and its lead asset HS235, a potential best-in-class activin receptor signaling inhibitor targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The acquisition strengthens GSK’s Respiratory, Immunology and Inflammation portfolio, addressing unmet needs in a high-burden disease with a growing market projected to reach $18 billion by 2032. GSK will pay $950 million in cash for 100% equity, subject to regulatory approvals, with closing expected thereafter. (Link)
  3. Exa Capital Expands Healthcare Software Portfolio with Acquisition of StaffReady, a Leader in Clinical Workforce Management SaaS Exa Capital, a long-term investor specializing in enterprise software, has acquired StaffReady, a SaaS platform for clinical workforce management in healthcare. Founded in 1995, StaffReady provides cloud-native tools for staff scheduling, compliance, and inspection readiness across hospital departments and life sciences organizations. The deal strengthens Exa Capital’s healthcare technology portfolio and marks its entry into clinical workforce optimization, a sector critical to operational efficiency and patient safety. StaffReady will continue to operate independently under Exa’s decentralized model, with its leadership team remaining in place to drive innovation and sustainable growth backed by Exa’s strategic support. (Link)
  4. Numantec Expands Infusion Therapy Portfolio with Acquisition of DualCap® Product Line from Merit Medical financed by Banco BPM and Muzinich & Co Numantec, a global infusion therapy device manufacturer, has acquired the DualCap® product line from Merit Medical Systems through its U.S. subsidiary, Health Line International Corp. The DualCap® is an established antimicrobial cap used in vascular access and infusion therapy, enhancing infection prevention and clinical efficiency. The acquisition strengthens Numantec’s vascular access portfolio and creates growth opportunities across Europe and the U.S., where DualCap® already has a strong customer base. Health Line, which has manufactured DualCap® since before 2017, will ensure continuity of supply. The transaction was financed by Banco BPM and Muzinich & Co. (Link)
  5. Healthcare Triangle (Nasd: HCTI) Announces $3.96 Million Registered Direct Offering Priced at-the-Market to Support Growth Initiatives Healthcare Triangle, Inc. (Nasdaq: HCTI), a digital transformation leader for healthcare and life sciences, announced it has entered into definitive agreements to sell 681,553 shares of common stock (or prefunded warrants) at $5.81 per share in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds are expected to total approximately $3.96 million before fees and expenses. The offering, conducted under the company’s effective Form S-3 shelf registration, is expected to close around February 27, 2026, subject to customary conditions. (Link)
  6. The HWP Group Acquires Global Market Access Solutions to Strengthen Market Access and Health Economics Expertise Backed by NMS Capital The HWP Group, a leading medical communications and strategic consulting firm for the life sciences sector, has acquired Global Market Access Solutions (GMAS), a global consultancy specializing in market access and health economics. The acquisition expands HWP’s capabilities in HEOR, pricing and payer insights, evidence synthesis, and lifecycle value strategy, enhancing support across the entire product lifecycle—from early development to sustained patient access. CEO Jani Hegarty said the deal reinforces HWP’s mission to bridge science and real-world access. Backed by NMS Capital, the move positions HWP as a fully integrated partner for pharmaceutical and biotechnology innovators. (Link)
  7. QC Capital Invests in My Pediatric Doctor to Expand Nationwide 24/7 Urgent Pediatric Telehealth Platform QC Capital Group, a Charlotte-based alternative investment firm, announced a strategic investment in My Pediatric Doctor, a nationwide 24/7 pediatric telehealth platform offering on-demand access to board-certified providers. Led by CEO Eric Doherty, the company aims to modernize pediatric care by reducing emergency room visits and improving accessibility for families across all 50 states, Guam, and Puerto Rico. The platform integrates with healthcare systems to relieve pressure on hospitals while maintaining high clinical standards. QC Capital CEO Chris Salerno called the partnership a key step in delivering trusted, affordable pediatric care nationwide. (Link)
  8. HCAP Partners Leads Follow-On Acquisition to Expand Integrated Diagnostic Services Platform with Core Analytics Lab & Radiology other partners include California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine San Diego-based private equity and impact investor HCAP Partners has completed a follow-on acquisition for its Integrated Diagnostic Services (IDS) platform with the addition of Santa Fe Springs-based Core Analytics Lab & Radiology. The deal expands IDS’s footprint into Northern California and adds mobile laboratory diagnostics to its service offerings. Financing was provided by HCAP Partners, California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine. Post-acquisition, IDS will serve over 440 facilities, offering bundled radiology and lab services to skilled nursing, long-term care, and home health providers across California. (Link)
  9. Gemspring Capital Expands Spinal Device Platform as Portfolio Company Zavation Medical Acquires ChoiceSpine Zavation Medical Products, a Gemspring Capital portfolio company and manufacturer of spinal implants and biologics, has acquired ChoiceSpine Holdings, a Knoxville-based spinal implant designer. The transaction broadens Zavation’s product portfolio and national reach, leveraging its vertically integrated manufacturing to accelerate innovation. ChoiceSpine will keep its brand and operations during integration. Concurrently, Zavation appointed Derek Kuyper as CEO of the combined entity. Gemspring Capital said the acquisition strengthens Zavation’s market position and supports its strategy to build a scaled, innovation-driven spinal platform. (Link)
  10. Fulcrum Equity Partners Leads $10M Growth Round in MedScout to Advance AI-Driven MedTech Sales Execution with participation from Live Oak Venture Partners and Stage 2 Capital Austin-based MedScout has raised $10 million in a growth funding round led by Fulcrum Equity Partners, with participation from Live Oak Venture Partners and Stage 2 Capital. The funding more than doubles MedScout’s valuation since its Series A in July 2024. The company also launched “Strategies,” a suite of AI agents designed to help MedTech commercial teams translate strategy into field-level execution. MedScout plans to use the capital to expand its AI capabilities amid surging enterprise demand. The company reported tripled enterprise revenue and rapid adoption growth as investors back its data-driven approach to commercial alignment in MedTech sales. (Link)
  11. Chapters Health Expands West Coast Footprint with Housecall Providers Deal, Strengthening Nonprofit Hospice Network and Growth Potential Chapters Health System, the nation’s largest nonprofit hospice network, has signed a definitive agreement to acquire Housecall Providers from CareOregon, pending approval by the Oregon Health Authority. The move expands its Pacific Northwest presence and adds to its 2025 West Division growth, which includes affiliates in California, Nevada, and Oregon. The integration aligns two nonprofit leaders in community-based chronic and homecare, reinforcing Chapters’ national scale, operational synergies, and value-based care capabilities—key drivers for investors tracking nonprofit healthcare consolidation and sustainable care delivery models. (Link)
  12. Dovida Enters U.S. Market with Acquisition of A Place At Home, Expanding Global Home Care Footprint to Seven Countries Global home care provider Dovida has entered the U.S. market through the acquisition of A Place At Home, a nationwide home care franchise network. The move marks Dovida’s seventh international market and first presence in North America, extending its person-centered care model across the United States. A Place At Home’s leadership will remain in place to ensure continuity for franchise owners and caregivers. The deal aligns with Dovida’s strategy to expand amid increasing demand for high-quality in-home care for older adults, reinforcing its mission to deliver personal, dignified, and relationship-based care on a global scale. (Link)
  13. Ally Bridge Group Backs Creation of Precision IO Group as Quantum Surgical Acquires NeuWave Medical to Advance Robotic Cancer Care Quantum Surgical has acquired NeuWave Medical, Inc., combining expertise in robotic and microwave ablation technologies under a new parent entity, Precision IO Group Inc., led by medtech veteran Kurt Azarbarzin. Supported by investment from Ally Bridge Group, the group aims to expand access to minimally invasive, AI-driven, and remote cancer treatments worldwide. Both companies will continue operating independently, ensuring ongoing product availability. The Epione robotic platform and NeuWave’s microwave system will together drive broader adoption of next-generation interventional oncology procedures across global healthcare markets. (Link)
  14. HIAAH Expands Mental Health Footprint with Strategic Acquisition of Broward Center for Counseling to Strengthen Market Presence in Broward County HIAAH, a U.S.-based integrated health care and mental health services provider, has acquired the Broward Center for Counseling as part of its expansion strategy in Broward County. The move reinforces HIAAH’s mission to broaden access to high-quality, compassionate mental health care while improving operational efficiency and client experience. The newly branded Broward Center for Counseling by HIAAH will continue providing individualized therapy for anxiety, depression, trauma, and relationship issues, now supported by enhanced infrastructure and a holistic, multidisciplinary care model. The acquisition aligns with HIAAH’s growth objectives and positions it for stronger long-term value creation in the behavioral health sector. (Link)
  15. UConn Health Finalizes Waterbury Hospital Acquisition from Prospect Medical Holdings UConn Health is set to complete its acquisition of Waterbury Hospital from bankrupt for-profit Prospect Medical Holdings at midnight on Saturday, marking a major expansion of its health network. The facility will operate under a new entity, UConn Health Community Network, beginning Sunday at 12:01 a.m. Immediate changes include new signage, updated processes, and a ribbon-cutting ceremony on March 4. UConn Health plans to assess Waterbury’s healthcare needs, modernize information and safety systems, and introduce new specialists and services from its flagship John Dempsey Hospital in Farmington to strengthen local medical care and patient outcomes. (Link)
  16. Bradford Health Expands into Midwest with Acquisition of Parkdale Center, Strengthening National Footprint in Specialized Professional Addiction Care Bradford Health Services, a nationally recognized addiction treatment provider, has acquired Parkdale Center, a leading Indiana-based facility specializing in confidential addiction recovery programs for healthcare providers, attorneys, executives, and other licensed professionals. The deal extends Bradford’s geographic reach into the Midwest and enhances its portfolio of evidence-based treatment offerings. Parkdale’s expertise in professional recovery, career reentry, and collaboration with licensing boards complements Bradford’s mission of clinical excellence and sustainable outcomes. Both organizations will maintain their brands while integrating operations to deliver expanded, high-quality care for professionals nationwide. Terms of the transaction were not disclosed. (Link)
  17. Zemantics Ventures Strengthens Healthcare Portfolio with Acquisition of Consilium360 and MedWell360 Zemantics Ventures, a strategic investment and operating platform, has acquired Consilium360 and MedWell360 to expand its presence in healthcare services and workforce solutions. The move enhances Zemantics’ capabilities in enterprise HR optimization, patient access, and technology-enabled operational performance. Consilium360 provides data-driven workforce and HR strategy solutions for healthcare systems, while MedWell360 specializes in scheduling and access center services. The acquisitions support Zemantics’ strategy of scaling founder-led, service-driven businesses through strategic capital, shared infrastructure, and technology. John Brown, Founder and Healthcare HR Executive, will continue in a leadership role to ensure continuity and growth. (Link)
  18. Epiphany Dermatology Expands Kansas Presence Through Partnership with Resolute Dermatology Epiphany Dermatology, a leading national dermatology network, has expanded its presence in Kansas by partnering with Resolute Dermatology, LLC, founded in 2020 by Dr. Daniel Christiansen. Based in Leawood and Shawnee, KS, Resolute Dermatology is recognized for high-quality patient care in the greater Kansas City area. The partnership brings Dr. Christiansen and his team—Drs. Julie Green, Elizabeth Spenceri, and PAs Judy Ky and Kylie Witham—into Epiphany’s growing network. Through this collaboration, Resolute gains operational and clinical support while sharing expertise across Epiphany’s 123 locations in 18 states, strengthening access to exceptional dermatologic care in the region. (Link)

Venture and Other News:

  1. NewSpring Healthcare Leads $140 Million Investment in Honest Health to Accelerate Value-Based Care Expansion included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners Honest Health, a physician-led value-based care enablement firm, raised $140 million in a funding round led by NewSpring Healthcare, the healthcare-focused arm of NewSpring Capital. The round included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners. Proceeds will support national expansion and partnerships with health systems and payers. NewSpring will leverage its sector expertise to guide Honest Health’s growth in risk-based care models. (Link)
  2. NantWorks Leads $240 Million Investment in SHINE Technologies; Dr. Patrick Soon-Shiong Joins Board to Advance Fusion and Cancer Therapies SHINE Technologies, a leader in fusion-based technology, has raised $240 million in new equity funding led by NantWorks, founded by Dr. Patrick Soon-Shiong, who also joins SHINE’s Board of Directors. Other investors include Fidelity, Sumitomo, Pelican Energy, Deerfield, and Oaktree. The funding supports SHINE’s commercial fusion initiatives in neutron testing, medical isotope production, and nuclear waste recycling, while accelerating Lu-177 radioisotope supply for precision cancer therapies. The strategic partnership gives NantWorks priority access to Lu-177, aligning SHINE’s fusion expertise with Soon-Shiong’s mission to transform oncology. With this round, SHINE’s total funding surpasses $1 billion. (Link)
  3. BrainCheck Secures Additional $13 Million Series A to Scale AI-Enabled Cognitive Care Platform and Embedded Assessment Workflows Across Value-Based Health Systems BrainCheck, a digital platform for cognitive assessment and care, has raised an additional $13 million in Series A financing led by Next Coast Ventures, with S3 Ventures and UPMC Enterprises participating. The capital will expand its enterprise cognitive care infrastructure, including deeper EHR integration, longitudinal monitoring, AI-assisted population health analytics, and deployment across primary care and specialty settings. BrainCheck is partnering with collaborative care organizations to operationalize scalable cognitive care pathways in time-constrained, value-based environments. Used by 500+ providers, its FDA Class II BrainCheck Assess™ has powered over 640,000 assessments and 14,000 care plans to date. (Link)
  4. YOU(th) Health Tech Raises $4.5M to Expand Smartphone-Based Preventive Health Screening Globally round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Digital health startup YOU(th) has raised $4.5 million in a funding round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Angel investors include Jean-Charles Samuelian (Alan, Mistral AI) and Patrick Andrae (HomeToGo). The company aims to democratize preventive healthcare by turning everyday smartphone data—such as facial videos, voice, typing patterns, and step counts—into quick health assessments detecting over 50 biomarkers across 10 organ systems. The funds will support product development and expansion of engineering, data science, and medical research teams to make preventive care accessible worldwide. (Link)
  5. General Catalyst Leads $6.5M Seed in Baba to Build Continuous AI‑Enabled Patient Advocacy for Aging Americans General Catalyst has led a more than $6.5 million seed round in Baba, a patient advocacy startup founded by Connor Sweeney to help seniors and families navigate complex healthcare logistics. Inspired by his grandparents’ experience after his grandmother’s stroke, Sweeney built Baba to pair older adults with dedicated human advocates, augmented by AI tools for daily check-ins, medication management, and insurance and benefits navigation. With advocacy reimbursed by Medicare for over 70 million beneficiaries, Baba aims to scale continuous, preventive support through partnerships with home health, nursing homes, and post-acute care providers. (Link)
  6. Coral Care Raises $13M Series A Led by Haymaker Ventures, Joined by FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures to Expand In-Home Pediatric Therapy Nationwide Coral Care, a platform providing in-home pediatric speech, occupational, and physical therapy, has raised a $13 million Series A round led by Haymaker Ventures, with participation from FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures. The funding will fuel national expansion in Dallas, Houston, Chicago, Philadelphia, and Pittsburgh, bringing operations to five states. Founded in 2023 by Jen Wirt, Coral Care supports over 400 licensed clinicians through its technology platform that streamlines administrative tasks and enables accessible, insurance-covered, in-home therapy for children across the U.S. (Link)
  7. AI Healthtech Startup Lexi Raises $1.4M Pre-Seed Round Led by Informed Ventures, Backed by HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures Lexi, an AI-native communication platform for healthcare, has raised an oversubscribed $1.4 million pre-seed round led by Informed Ventures, with participation from HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures. Founded by Linh Pham and Siddharth UR, Lexi tackles language barriers affecting 30 million U.S. patients by providing secure, instant AI interpretation within clinical workflows. A successful pilot with Lowell Community Health Center delivered over 60,000 minutes of interpretation, reduced costs by 60%, and improved privacy and efficiency. Lexi plans to expand deployments across health centers while broadening language coverage and patient partnerships. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 23rd, 2026

LECO_Weekly-Healthcare-News_2.23.2026Download
  1. Trump’s Section 122 Tariffs Hit UK, EU Hardest as Supreme Court Strikes Down IEEPA Levies, Benefiting Brazil, China, India The U.S. Supreme Court ruled 6-3 that President Trump wrongly used IEEPA for tariffs, prompting a shift to 15% global duties under Section 122 of the 1974 Trade Act. Trade-weighted averages rise for UK (+2.1 points), EU (+0.8), Japan (+0.4), South Korea (+0.6), while plunging for Brazil (-13.6), China (-7.1), and India. Experts note heaviest IEEPA-hit nations gain most relief; early deal-makers suffer hikes. EU seeks clarity on prior 15% cap deal. China assesses; India delays trade talks. (Link)
  2. Blue Owl Capital Shares Slide Again as Debt Fund Liquidity Changes and $1.4B Asset Sale Heighten Private Credit Concerns Blue Owl Capital’s stock extended its recent selloff as investors reacted to the firm’s strategy to return capital from one of its private debt funds following a $1.4 billion loan portfolio sale. The alternative asset manager adjusted redemption mechanics for Blue Owl Capital Corp II, opting to return capital through asset sales rather than traditional quarterly liquidity windows. The developments have fueled broader concerns around liquidity, valuation transparency, and structural risks within retail-oriented private credit vehicles. The market reaction underscores growing scrutiny of private credit managers as fundraising slows and pressures rise. (Link)
  3. Cristiano Ronaldo Invests $7.5 Million in Herbalife’s (NYSE: HLF) Pro2col AI Wellness Tech, Secures 10% Stake in Key Subsidiary Herbalife Ltd. (NYSE: HLF) announced soccer superstar Cristiano Ronaldo’s $7.5 million investment in HBL Pro2col Software, LLC, gaining a 10% equity stake. The deal includes service and sponsorship commitments, highlighting Ronaldo’s faith in Pro2col’s AI-driven, personalized wellness platform. Since partnering with Herbalife in 2013, Ronaldo endorsed products like Herbalife24 CR7 Drive. Pro2col uses data for custom plans, tracks habits via Pro2Score, and aids distributors. Now in U.S., Canada, and Puerto Rico beta and expanding to EMEA, boosting their data-centric strategy. (Link)
  4. True North PE Injects INR 150Cr ($16.5M) into High-Growth ACN Healthcare RCM; $20M More Eyed as India’s Outsourcing Boom Accelerates True North Private Equity’s Credit Opportunities Fund I invests Rs 150 crore in ACN Healthcare RCM, a top Revenue Cycle Management provider with India operations and US clients. ACN boasts 68% CAGR growth over three years, employing 3,000+ professionals across four centers. Funds will fuel service expansion, strategic moves, and new facilities. More PE funds eye up to $20M in the round. India’s RCM market surges at 15-17% CAGR, driven by outsourcing, AI, and global demand, with India holding 50% of worldwide talent amid healthcare complexities. (Link)
  5. Danaher (NYSE: DHR) to Acquire Masimo (NASDAQ: MASI) in $9.9 Billion Cash Deal at $180/Share, Boosting Diagnostics with Pulse Oximetry Leader Amid Expected Synergies Danaher Corporation (NYSE: DHR) has agreed to acquire Masimo Corporation (NASDAQ: MASI) for $180 per share in cash, valuing the deal at $9.9 billion enterprise value. The acquisition bolsters DHR’s Diagnostics segment with MASI’s pulse oximetry and patient monitoring tech, expecting high-single-digit revenue growth, $530M+ 2027 EBITDA, $125M cost synergies, and $50M revenue synergies by year five. Deal closes H2 2026 pending approvals; accretive to EPS by $0.15-$0.20 year one, $0.70 by year five. (Link)
  6. Johnson & Johnson (NYSE:JNJ) Explores $20 Billion Sale of DePuy Synthes Orthopedics Unit Amid Spinoff Plans Johnson & Johnson (JNJ.N) is preparing to sell its orthopedics unit, DePuy Synthes, in a deal potentially exceeding $20 billion, targeting private equity firms as top buyers, Reuters reports. The unit, which generated $9.3 billion in 2025 sales from hip, knee, and shoulder implants, was slated for a standalone spinoff within 18-24 months to focus on high-growth segments. J&J is assembling financials for upcoming buyer meetings; large PE firms may team up, with interest from medical device rivals possible. This follows resolutions of most ASR hip lawsuits. CFO eyes tax-free spinoff but open to sales. (Link)
  7. PE-backed Elevate Patient Financial Solutions acquires Centauri Health Solutions’ health systems services unit, expanding Medicaid eligibility, enrolment and complex revenue cycle capabilities across U.S. hospital clients Private equity–backed Elevate Patient Financial Solutions has agreed to acquire Centauri Health Solutions’ Health Systems Services (HSS) unit, a Phoenix-based provider of specialized eligibility and enrollment services for Medicaid and disability programs, out-of-state Medicaid billing, and complex revenue cycle solutions for hospitals and health systems. The deal strengthens Elevate PFS’s position in patient financial engagement and government program eligibility, broadens its national footprint, and is expected to drive cross-selling opportunities across existing provider relationships while supporting uncompensated-care and Medicaid-reliant populations. (Link)
  8. TriSalus Life Sciences (Nasdaq: TLSI) Prices $40M Common Stock Offering at $4.10/Share with 15% Over-Allotment Option, Closing February 23, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) priced its underwritten public offering of 9,756,100 common shares at $4.10 each, expecting $40 million in gross proceeds before expenses. The oncology-focused medtech firm granted underwriter Lake Street Capital Markets a 30-day option for 1,463,415 additional shares (15% of the offering). Closing is set for February 23, 2026, subject to conditions, via an effective S-3 shelf registration. Funds will support general corporate purposes, amid devices like TriNav for tumor drug delivery and nelitolimod immunotherapy research. (Link)
  9. CenterWell, the healthcare services division of Humana Inc. (NYS: HUM) Expands Florida Footprint with Acquisition of MaxHealth from Arsenal Capital Partners CenterWell, the healthcare services division of Humana Inc., has completed its acquisition of MaxHealth from private equity firm Arsenal Capital Partners and the company’s founder-shareholders. The deal strengthens CenterWell’s presence in Florida, adding a network of 54 owned primary care clinics, four specialty centers, and 24 affiliate clinics across West and South Florida. MaxHealth serves over 120,000 patients, including more than 80,000 in value-based care programs. The acquisition aligns with CenterWell’s strategy to expand its integrated, patient-centered care delivery network and enhance access to high-quality, coordinated healthcare services for seniors and other patients across the region. (Link)
  10. CSD Acquires New Mexico’s Leading Autism Provider BCI in Strategic Merger to Boost Southwest Access, Innovation, and Evidence-Based Behavioral Care Nationwide via its financial sponsors NMS Capital, CD Private Equity, and Goldman Sachs Asset Management Center for Social Dynamics (CSD), a top national autism therapy provider, has acquired Behavior Change Institute (BCI), New Mexico’s premier autism care organization known for clinical expertise and equitable access. Announced February 19, 2026, the deal unites research-driven models, shortening wait times and blending in-person, virtual, and tech-enhanced therapies. CSD CEO Kelly Bozarth hailed it as a “values-driven union” for faster breakthrough care. BCI leaders emphasized scaling their mission nationally while preserving clinical culture. Families retain teams with added CSD tools; the merger advances research, clinician training, and outcomes in underserved areas. (Link)
  11. VB Spine LLC Acquires Exclusive Rights to Augmedics’ FDA-Cleared xvision Spine System®, Bolstering AR Navigation Leadership in Spine Surgery with Nearly 13,000 Cases of Proven Use VB Spine LLC, the largest privately held spine company, announced a definitive agreement to acquire exclusive rights to Augmedics’ groundbreaking xvision Spine System®, the first FDA-cleared AR navigation platform for spine surgery. This move enhances VB Spine’s visualization portfolio, following its recent SpineHawk™ acquisition, and positions it as a global leader in AR-enabled solutions. xvision offers direct-patient visualization, precision, workflow efficiency, and radiation reduction, with nearly 13,000 procedures completed. The deal, expected to close soon pending approvals, supports VB Spine’s strategy to redefine spine care. (Link)
  12. St. David’s HealthCare Acquires Cardiothoracic and Vascular Surgeons, Strengthening Central Texas Cardiovascular Expertise in Strategic Integration Austin-based St. David’s HealthCare, part of HCA Healthcare and local nonprofits, has acquired Cardiothoracic and Vascular Surgeons (CTVS) on Feb. 15. The system, with nine hospitals, 190 care sites, and over 12,600 employees, will keep CTVS’s name, operations, physicians, providers, and 45 staff intact while aligning them under St. David’s. “This integration builds on decades of collaboration to elevate care and innovation,” said CEO David Huffstutler. The move advances cardiovascular standards in Central Texas. (Link)
  13. Epiphany Dermatology Expands Missouri Footprint with Strategic Partnership Joining Regional Dermatology’s St. Louis Clinics in Chesterfield and Festus Epiphany Dermatology has partnered with Regional Dermatology, LLC, founded in 2010 by board-certified dermatologist Sarah Jensen, M.D., to boost its presence in Missouri’s St. Louis market. The deal integrates Jensen’s team—including two advanced practice providers—at two locations: Chesterfield (West) and Festus. This enhances access to high-quality dermatology services like general care, skin cancer treatment, and Mohs surgery. Jensen praised Epiphany’s patient-focused values, while CEO Gheorghe Pusta highlighted the cultural fit and shared expertise. Epiphany now supports operations, marketing, and recruiting, operating 121 locations across 18 states from Austin, Texas. (Link)
  14. Gilead to Acquire Arcellx for Up to $7.8 Billion, Expanding Oncology and Cell Therapy Pipeline Gilead Sciences has agreed to acquire Arcellx in a transaction valued at up to $7.8 billion, strengthening its position in next-generation cell therapies for cancer. Arcellx’s lead programs focus on innovative immunotherapy approaches designed to improve durability and safety in hematologic malignancies. The acquisition builds on Gilead’s broader oncology strategy and deepens its commitment to high-growth, high-innovation therapeutic areas. The deal underscores continued large-cap biopharma appetite for differentiated oncology assets amid competitive cell therapy development. (Link)
  15. Viventium Acquires Apploi to Launch Unified HCM Platform Revolutionizing Post-Acute Care Workforce Management Amid Labor Crisis via its financial sponsor LLR Partners Viventium has acquired Apploi, creating a category-leading human capital management (HCM) platform tailored for post-acute and long-term care providers. The unified system integrates recruiting, credentialing, onboarding, payroll, scheduling, and compliance across all 50 states, addressing labor shortages and fragmented software silos. Viventium CEO Navin Gupta highlighted ending “fractured systems,” while Apploi CEO Adam Lewis emphasized full employee lifecycle support. Serving thousands of providers and hundreds of thousands of employees, the deal closed January 30, 2026. Financial terms undisclosed. (Link)
  16. Invo Fertility (Nasdaq: IVF), Acquires Indianapolis’ Family Beginnings for $760K, Bolstering Midwest Presence and Projecting $9M Clinic Revenue in 2025 Amid Growth Pivot Invo Fertility Inc. (Nasdaq: IVF), based in Sarasota, has acquired the nonclinical assets of Midwest fertility clinic Family Beginnings in Indianapolis for $760,000 in cash and preferred stock. The deal preserves Dr. James Donahue’s leadership and the existing team, with Invo providing operational support and tech investments. Family Beginnings reported $1M revenue and $200K net income for the nine months ended Sept. 30, 2025—18% of Invo’s clinic revenue. Now with four clinics, Invo eyes $9M combined 2025 revenue, up from 2024’s $6.5M total (with $9.1M net loss). CEO Steve Shum calls it an “inflection point,” targeting acquisitions, organic growth, and 2026 expansion via marketing and tech. (Link)
  17. Northwell Health Bolsters South Shore Presence with $9.5M Off-Market Acquisition of Merrick Orthopedic Office Building from Berkeley Capital Northwell Health has expanded its real estate holdings by acquiring a 17,714-square-foot medical office building at 1728-1732 Sunrise Highway in Merrick for $9.5 million in an off-market deal. The property, on 0.46 acres, houses Northwell affiliate Orlin & Cohen Orthopedic Group, with about three years remaining on its lease. Northwell, self-represented, bought from Berkeley Capital LLC, represented by North Village Realty’s Tom Bigansky. The move secures long-term healthcare delivery in South Shore communities, reflecting generational planning and market confidence, Bigansky noted. (Link)
  18. Sensei Biotherapeutics (Nasdaq: SNSE) Acquires Faeth Therapeutics in $200M-Backed Deal to Advance PIKTOR Cancer Therapy Sensei Biotherapeutics (Nasdaq: SNSE) has acquired Faeth Therapeutics, gaining its lead asset PIKTOR—an investigational all-oral combo of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancers. Concurrently, Sensei secured $200 million in Series B preferred stock financing from top investors like RA Capital, Vivo Capital, and Cormorant. Proceeds will fund Phase 2 topline data in endometrial cancer and a Phase 1b breast cancer trial by end-2026, plus ongoing solnerstotug studies. Post-deal, Faeth holders own 40.8%, investors 54.3%, and prior Sensei shareholders 4.9% on a fully diluted basis. (Link)
  19. Kinderhook Industries to Take Home Health and Hospice Provider Enhabit (NYSE: EHAB) Private in $1.1B Deal Private equity firm Kinderhook Industries has agreed to acquire Enhabit Inc., a Dallas-based home health and hospice services provider, in a transaction valued at approximately $1.1 billion. Under the terms of the deal, Enhabit shareholders will receive $13.80 per share in cash, representing a premium to the company’s recent trading levels. The transaction is expected to close in Q2 2026, at which point Enhabit’s shares will be delisted from the NYSE. The acquisition reflects continued PE interest in the home health and hospice sector amid demographic tailwinds and demand for at-home care services. (Link)

Venture and Other News:

  1. Rainfall Health Secures $15M Series A to Supercharge AI Compliance Platform Amid CMS’s TEAM Mandate Launch, Unlocking $100M+ Revenue for Hospitals Rainfall Health, an AI-driven compliance platform for hospitals, closed a $15 million Series A round led by Two Bear Capital. The funding will expand AI and customer support teams to aid providers under CMS’s new Transforming Episode Accountability Model (TEAM), launched January 1, 2026. TEAM targets high-cost surgeries like joint replacements and spinal fusions, offering 20% revenue boosts—over $100 million per health system—for meeting quality metrics. CEO Eddie Qureshi emphasized high-quality post-acute care. Backed by experts like former VA Secretary David Shulkin, Rainfall sets a national standard for value-based reimbursement and patient outcomes. (Link)
  2. ProSomnus Secures $38 Million Strategic Investment from Catalio Capital to Advance Next‑Generation Smart Sleep Medicine Platform ProSomnus Sleep Technologies, a leader in non‑CPAP Obstructive Sleep Apnea (OSA) therapy, announced a $38 million strategic investment from healthcare investor Catalio Capital Management to accelerate global expansion and technology development. The funding will support next‑generation remote patient monitoring, proprietary sleep diagnostic devices, and comparative clinical studies. CEO Len Liptak emphasized that the partnership validates ProSomnus’s mission to deliver data‑driven, patient‑preferred OSA therapies. CFO Jason Orchard noted the investment will optimize infrastructure and enhance patient outcomes. Catalio’s Dr. Nicholas von Guionneau joins as Board Observer, highlighting ProSomnus’s leadership in connected, precision sleep solutions. (Link)
  3. Dallas-Based SpendRule Exits Stealth with $2M Seed Round from Abundant Venture Partners, MemorialCare Innovation Fund, and Zeal Capital Partners to Automate AI-Powered Contract Compliance and Invoice Validation for Hospitals like OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health SpendRule, founded by Chris Heckler and Joseph Akintolayo, automates contract compliance and invoice validation for health systems. Its AI software checks purchased services invoices against contract terms pre-payment, integrating seamlessly with ERP systems, contract management, and accounts payable workflows. The funding will expand the team and advance AI infrastructure. Backed by Abundant Venture Partners—a Chicago VC focused on healthcare innovation with a network of 22+ provider organizations—SpendRule serves major clients including OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health. (Link)
  4. Covetrus and MWI Animal Health Strike $3.5 Billion Merger Deal, Forming Tech-Enhanced Platform with Cencora Retaining Major Stake Covetrus and MWI Animal Health announced a blockbuster $3.5 billion merger on February 18, creating a unified “comprehensive animal health platform.” MWI’s owners, Cencora, will receive $1.25 billion in cash and equity stakes, retaining a 34.3% share in the new entity. Leaders hailed the deal for blending MWI’s supply chain prowess and customer ties in companion and production animal sectors with Covetrus’ tech-driven veterinary solutions. The combo promises enhanced logistics, cost savings, broader customer reach—from vets and producers to pet owners—and accelerated innovation to make animal care more affordable and accessible. (Link)
  5. Grail’s Galleri Multi-Cancer Early Detection Blood Test Misses Primary Endpoints in Large Screening Trial Grail’s Galleri multi-cancer early detection blood test recently failed to meet its primary endpoints in a large clinical screening study, raising doubts about its effectiveness as a broad population screening tool. Following the release of these results, the company’s stock experienced a significant decline as investors reassessed commercial prospects. The data suggested lower than expected sensitivity for detecting certain cancers, which could complicate regulatory and reimbursement pathways. The outcome underscores ongoing challenges for next-generation liquid biopsy tests in proving clinical utility at scale. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 16th, 2026

LECO_Weekly-Healthcare-News_2.16.2026Download
  1. Eli Lilly (NYSE: LLY) acquires Orna Therapeutics for up to $2.4 billion to enter in vivo CAR-T therapy market The all-cash acquisition gives Lilly access to Orna’s engineered circular RNA platform combined with lipid nanoparticles to generate cell therapies within patients’ bodies. Orna’s lead asset, ORN-252, targets CD19 for B-cell-driven autoimmune diseases and is described as clinical trial-ready. Founded in 2021 with technology from MIT researchers Alex Wesselhoeft, Ph.D. and Professor Dan Anderson, Ph.D., Massachusetts-based Orna raised $321 million across seed and Series B rounds and established collaborations with Merck & Co. and Vertex. The platform aims to deliver more durable therapeutic protein expression than current RNA or cell therapy approaches, addressing complexity and cost challenges of ex vivo CAR-T therapies. (Link)
  2. Sanofi (NASD: SNY) completes acquisition of Dynavax Technologies at $15.50 per share The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, currently marketed in the U.S. with a differentiated two-dose regimen over one month, along with shingles vaccine candidate Z-1018 in phase 1/2 studies and additional vaccine pipeline projects. The tender offer expired on February 9, 2026, and Sanofi accepted all validly tendered shares on February 10, 2026. Following the merger under Delaware General Corporation Law Section 251(h), Dynavax became an indirect, wholly owned subsidiary of Sanofi. The transaction augments Sanofi’s adult immunization presence by combining Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities. (Link)
  3. Waters Corporation (NYSE: WAT) completes combination with BD’s Biosciences & Diagnostic Solutions (NYSE: BDX) businesses through Reverse Morris Trust transaction, forming global life sciences and diagnostics leader The transaction creates a combined company with Waters shareholders holding 60.8% and BD shareholders owning 39.2% on a fully diluted basis. Waters has established four divisions: Waters Analytical Sciences (separations science and mass spectrometry), Waters Biosciences (flow cytometry and single cell multiomics), Waters Advanced Diagnostics (microbiology, molecular, and multiplex testing), and Waters Materials Sciences (thermal analysis and rheology). The company also appointed Dr. Claire M. Fraser, an internationally recognized genome scientist and former Director of The Institute for Genome Sciences at University of Maryland, to its Board of Directors, expanding the board to 11 members. (Link)
  4. Harbor Health acquires Rippl with continued backing from Kin Ventures, ARCH Venture Partners, General Catalyst, GV, F-Prime Capital, JSL Health and Mass General Brigham Ventures to expand dementia support services The acquisition expands Harbor Health’s condition-focused care pathways into dementia management and extends its geographic footprint into Florida, building on its 2025 purchase of 32 VillageMD clinics. Rippl’s dementia care platform helps seniors remain at home while avoiding unnecessary emergency department visits, hospitalizations, and post-acute care through early identification of medical and behavioral issues. The program will be available at Harbor Health and VillageMD locations in Austin, Dallas, San Antonio, and El Paso for Medicare Advantage members and traditional Medicare beneficiaries through CMS’ GUIDE program, supporting Harbor Health’s proactive, integrated care-and-coverage model. (Link)
  5. Patient Square Capital signs definitive agreement to acquire Paradigm from OMERS Private Equity The transaction reflects Patient Square’s long-standing relationship with Paradigm’s leadership and confidence in the company’s ability to manage complex, high-acuity cases while delivering measurable cost savings and improved outcomes. Walnut Creek-based Paradigm is a specialty care management organization focused on individuals with complex injuries and diagnoses, with growing leadership in payment integrity, home health, and network services across workers’ compensation and healthcare payer sectors. The acquisition marks the successful conclusion of Paradigm’s partnership with OMERS Private Equity. Patient Square will support Paradigm’s expansion beyond its proven workers’ compensation model into the broader healthcare landscape under CEO John S. Watts, Jr.’s leadership. (Link)
  6. ReviveHealth acquires Doseform, via its financial sponsor Eir Partners, to integrate AI driven automation and patient engagement platform across pharmacy operations The acquisition establishes Doseform as the patient management system for Revive’s Pharmacy Centers of Excellence, with deployment planned across all pharmacy locations. Founded in 2021, Doseform uses AI-driven two-way messaging to streamline prescription workflows, payments, and patient communications through automated SMS and mobile links. The platform enables patients to view prescriptions, confirm orders, complete intake forms, and submit payments directly from phones without portals or apps. It addresses routine questions about refills, copays, and order status through AI-enabled chat, reducing inbound call volume and allowing pharmacy teams to focus on higher-value services while supporting rapid growth and operational efficiency. (Link)
  7. Traumasoft acquires Huly, via its financial sponsor Serent Capital, to advance AI strategy for EMS industry Huly will retain its independent brand, leadership team, and R&D operations under Founder and CEO Nidhish Dhru, remaining accessible to EMS agencies regardless of their technology stack. The AI-native platform automates time-intensive administrative processes across pre-billing, Quality Assurance/Quality Improvement, and payroll workflows. Agencies using Huly report first-time billing rejections dropping from approximately 60% to near 10%, along with improved cash flow, accuracy, and staff productivity. Traumasoft customers will benefit from tightly integrated workflows connecting HMS, billing, QA/QI, and AI-driven automation. The structure allows Huly to innovate across the EMS ecosystem while delivering value within Traumasoft’s platform. (Link)
  8. Humana Health’s (NYSE: HUM) CenterWell completes acquisition of MaxHealth from Arsenal Capital Partners to expand senior-focused primary care network The Florida-based primary care organization operates 54 owned primary care clinics, 4 owned specialty/ancillary clinics, and 24 downstream affiliate clinics throughout West and South Florida, serving more than 120,000 patients including over 80,000 in value-based care programs. MaxHealth will now be affiliated with CenterWell Senior Primary Care, the nation’s largest senior-focused, value-based primary care provider, expanding CenterWell’s reach into new key markets. MaxHealth will continue operating under CEO Michelle Leslie’s leadership. (Link)
  9. Abound Health acquires Pro Care Unlimited, via its financial sponsors Housatonic Partners, Peterson Partners, The Cambria Group, Trilogy Search Partners, WSC & Company, Relay Investments, Aspect Investors and Endurance Search Partners, to expand intellectual and developmental disability services into Michigan Effective January 1, 2026, Michigan-based Pro Care Unlimited joined Abound Health while retaining its current name and leadership. Pro Care will gain access to Abound’s infrastructure, clinical oversight, leadership development programs, direct care worker recognition initiatives, emergency assistance through Abound Cares, and scholarships and training resources. Founded over 20 years ago in North Carolina, Abound Health now serves more than 6,000 individuals across North Carolina, Pennsylvania, New Jersey, and Michigan with over 7,500 team members. The acquisition aims to build one of Michigan’s most robust IDD networks. (Link)
  10. Natus Sensory acquires TheraB Medical to expand neonatal phototherapy portfolio with FDA-cleared wearable technology The acquisition adds TheraB Medical’s SnugLit™, the first FDA-cleared wearable phototherapy system designed as a single swaddle-style garment for treating neonatal jaundice, to Natus Sensory’s newborn care portfolio. SnugLit received FDA 510(k) clearance in January 2026 and enables infants to remain close to caregivers during treatment, supporting bonding and family-integrated care models. The wearable device complements Natus Sensory’s existing hospital-based phototherapy solutions, providing clinicians greater flexibility to tailor treatment across hospital and home-care settings. Natus Sensory’s global presence and established hospital relationships will enable access to innovative technology for families and clinicians. (Link)
  11. HealthMark Group acquires Purview, via its financial sponsors Aspect Investors, WSC & Company, Ridgemont Equity Partners, TA Associates Management, Saltoun Capital Partners and BaseFour, to expand digital access to medical imaging and modernize image sharing infrastructure The acquisition addresses the healthcare industry’s persistent reliance on physical discs for medical image sharing, with approximately two-thirds of radiological images still distributed this way. Purview’s cloud-based platform simplifies ingestion, analysis, and sharing of medical imaging data, providing quick and secure access to imaging records regardless of care delivery location. Trusted by numerous academic medical centers and five of the top ten children’s hospitals, Purview will integrate into HealthMark’s clinical data exchange solution to provide complete, timely access to medical imaging across regions, institutions, and care settings, accelerating care delivery and improving patient outcomes for authorized recipients. (Link)

Venture and Other News  

  1. Talkiatry raises oversubscribed $210M Series D led by Perceptive Advisors with Sofina, Andreessen Horowitz and Left Lane Capital to expand telepsychiatry services The New York City-based company will use proceeds to build technology and expand services across the mental health acuity spectrum, including lower-acuity offerings like couples therapy and future higher-acuity services such as intensive outpatient support. Talkiatry directly employs over 800 full-time psychiatrists and is in-network with more than 100 insurers covering over 170 million lives, delivering 3 million patient visits to date. The company’s Mindshare Partner Program partners with over one-third of the country’s top 20 health systems, enabling patient referrals while integrating with existing EMR systems and workflows, achieving cost reductions up to $700 per member per month. (Link)
  2. Solace Health raises $130M Series C led by IVP with Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures to scale patient advocacy platform at $1B valuation Founded in 2022, Solace Health will use proceeds to expand its national advocate network beyond 2,000 existing advocates, invest in platform and clinical research, and deepen payer and provider partnerships to embed advocacy earlier in patient journeys. The digital platform matches Medicare and Medicare Advantage patients with trained healthcare advocates who coordinate care, manage appointment logistics, attend appointments, reduce medical bills, organize documents, manage insurance appeals, and oversee care transitions. Serving over 20,000 patients monthly, 98% report better outcomes, with 95% paying no out-of-pocket costs for services. (Link)
  3. Garner Health raises $118M Series D led by Kleiner Perkins with Redpoint, Maverick, Kaiser Permanente Ventures, Mercy and Plus Capital to scale AI-driven care navigation platform at $1.35B valuation The New York-based company will use proceeds to expand its proprietary doctor ranking platform, scale AI-driven navigation and appointment booking capabilities, and grow its team. Garner leverages medical data covering over 320 million patient records to identify high-performing doctors who follow latest research and avoid unnecessary procedures, showing top providers have 75% lower complication and mortality rates. The platform acts as a financial administrator layering atop existing health plans, covering out-of-pocket costs when employees see top providers. This results in employees paying 80% less while employers achieve 12% total healthcare cost reduction, serving over 2.5 million members across 700 clients. (Link)
  4. Anterior raises $40M funding round led by FPV and Kinnevik with NEA and Sequoia Capital to scale AI platform for health insurers The round brings Anterior’s total funding to $64 million as the company expands its clinician-led AI platform that supports health plans with prior authorization, payment integrity, and risk adjustment workflows. Founded by physician and former Google product leader Dr. Abdel Mahmoud, Anterior deploys AI directly into clinical workflows with a team comprising 40% clinicians who contribute to the codebase. The company has deployed across major U.S. health plans including Geisinger Health Plan, built strategic integrations with HealthEdge, and supports organizations covering 50 million lives through its Forward Deployed Clinician model that pairs advanced technology with embedded clinical expertise. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 9th, 2026

LECO_Weekly-Healthcare-News_02-09-2026Download
  1. Weight-loss drugs to compete on biggest stage with Super Bowl ads (Link)
    • Official NFL Super Bowl Commercials 2026 – All Commercials (Link)
      • Novo Nordisk (Wegovy): Celebrity-filled oral weight-loss pill promo. (Link)
      • Hims & Hers: Highlights wealth-health inequality gap. (Link)
      • Ro: Serena Williams promotes GLP-1 telehealth. (Link)
      • Novartis: Encourages prostate cancer blood test screening. (Link)
      • Boehringer Ingelheim: Raises awareness for kidney disease screening. (Link)
  2. TrumpRx launches with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to offer discounted drugs for U.S. cash‑paying patients under Most favoured Nation policy
    The TrumpRx direct‑to‑consumer platform introduces over 40 discounted prescription drugs to help uninsured or cash‑paying U.S. patients access more affordable treatments. The initiative, backed by the first five pharmaceutical companies signing pricing deals under the Most Favoured Nation policy, includes major blockbusters such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both offered at significantly reduced prices. Additional products include insulin, fertility therapies, and inhalers from Pfizer and others. Sixteen global drugmakers are expected to join the platform, which aims to align U.S. medication prices with international standards while reshaping the domestic pricing landscape and consumer access dynamics. (Link)
  3. Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
    Takeda Pharmaceutical enters multi-year AI drug discovery collaboration with Iambic Therapeutics worth more than $1.7 billion to accelerate small-molecule development in oncology, inflammation, and gastrointestinal diseases. The partnership underscores Takeda’s push to fully integrate AI into its R&D engine, following prior deals like its Nabla Bio collaboration, as big pharma bets on AI to speed discovery, reduce costs, and target complex diseases more precisely. Iambic, a San Diego-based biotech with a growing pipeline of AI-discovered candidates, gains validation and funding to expand its platform amid surging interest in AI-driven drug design. (Link)
  4. Once Upon a Farm (NYSE: OFRM) raises $198M in NYSE IPO backed by Goldman Sachs and J.P. Morgan to expand organic children’s food business co-founded by Jennifer Garner
    The company’s public debut marks a major milestone for the organic children’s food brand, offering 11 million shares at $18 each. Founded by Cassandra Curtis and Ari Raz in 2015 and later joined by Jennifer Garner and John Foraker, Once Upon a Farm produces cold-pressed pouches, frozen meals, and oat bars made from responsibly sourced fruits and vegetables. The IPO strengthens its ability to meet rising consumer demand for clean, nutritious food products while amplifying its retail presence. Despite global supply challenges, the company aims to grow amid increasing momentum in the health-conscious food and beverage market. (Link)
  5. TenetHealthcare (NYSE: THC) receives $1.9B from CommonSpirit to regain full ownership of Conifer Health Solutions
    Under the agreement, CommonSpirit will pay Tenet Healthcare $1.9 billion in instalments over three years to sell its 23.8% equity stake in Conifer Health Solutions, Tenet’s revenue cycle management subsidiary. The transaction, retroactive to January 1, 2026, also includes a $540 million payment from Conifer to eliminate CommonSpirit’s capital account and finalize the stake redemption. Conifer will continue providing services to CommonSpirit through the end of 2026 while onboarding new clients. Tenet expects the move to strengthen its financial outlook, citing operational efficiency, revenue growth, and strategic alignment as key drivers for sustaining profitability and future expansion. (Link)
  6. PrimeGen US to merge with DT Cloud Star Acquisition Corporation (NASD: DTSQ) in a $1.5B business combination to accelerate stem cell and exosome therapy development
    The merger will position PrimeGen US for public market access and expanded funding to advance its regenerative medicine portfolio. The company’s lead program centers on its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform, being developed as a treatment for acute alcoholic hepatitis and other liver-related conditions. The deal, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will support clinical progression, regulatory submissions, and potential commercialization. PrimeGen’s leadership emphasized that the transaction marks a major step toward scaling its two-decade foundation in stem cell innovation into transformative therapies for critical diseases. (Link)
  7. Eikon Therapeutics (NASD: EIKN) raises $381M in upsized Nasdaq IPO, the largest biotech listing since 2024, led by former Merck executive Roger Perlmutter
    Proceeds from the public offering will fund the clinical advancement of Eikon’s oncology pipeline, notably EIK1001, a toll-like receptor 7/8 agonist currently studied with Keytruda in melanoma and lung cancer. Additional programs include PARP1 inhibitors EIK1003 and EIK1004—targeting ovarian, breast, prostate, and pancreatic cancers—and EIK1005, a WRN helicase inhibitor in early-stage development for solid tumours. The company, founded in 2021, continues to build momentum on its immunotherapy and precision oncology strategy, backed by prior multimillion-dollar financing rounds that have supported rapid progression from preclinical research to multiple active phase 1/2 and 2/3 trials across critical cancer indications. (Link)
  8. SpyGlass Pharma (NASD: SGP) launches $150M Nasdaq IPO for advancing long-acting eye drug delivery innovation
    Funds from the IPO will advance SpyGlass Pharma’s lead candidate, the Bimatoprost Drug Pad-IOL System, a long-acting intraocular lens designed to deliver sustained treatment for glaucoma and ocular hypertension. The device, implanted during cataract surgery, provides years of drug release, potentially eliminating the need for daily eye drops. Proceeds will support two phase 3 clinical trials already underway and a potential commercial rollout upon successful results. Early studies demonstrated significant intraocular pressure reduction, affirming the platform’s promise. SpyGlass joins a wave of biotech companies reinvigorating the IPO market as investors renew interest in ophthalmic and drug-delivery innovations. (Link)
  9. Agomab Therapeutics (NASD: AGMB) raises $200M in Nasdaq IPO to support development of ALK5 inhibitors for fibrostenosing Crohn’s disease and pulmonary fibrosis
    Proceeds from the IPO will fund Agomab Therapeutics’ next-stage clinical programs, including a global phase 2b trial for ontunisertib, its leading oral ALK5 inhibitor targeting fibro stenosing Crohn’s disease. The company also plans to advance AGMB‑447, another ALK5 inhibitor in phase 1 studies for idiopathic pulmonary fibrosis, toward midstage development. Both candidates were obtained through Agomab’s 2021 acquisition of Origo Biopharma. The IPO proceeds will also bolster operational growth and global research capabilities as Agomab pursues fibrosis-modifying therapies aimed at halting disease progression in patients with chronic intestinal and respiratory conditions. (Link)
  10. Veradermics (NYSE: MANE) raises $256M in NYSE IPO with investment interest from Eli Lilly and Wellington Management to advance oral minoxidil hair regrowth therapy
    The Connecticut-based biotech’s IPO marks a strong debut, with shares more than doubling in their first trading session. Veradermics focuses on developing VDPHL01, an extended-release oral version of minoxidil, intended to overcome limitations of topical Rogaine. The funds will support phase 3 trials evaluating its efficacy in treating pattern hair loss. Eli Lilly expressed interest in acquiring up to 4.9% of issued shares, while Wellington Management indicated plans to invest up to $30 million. The company seeks to capture a major share of the expanding global hair loss market and lead innovation in convenient, effective hair restoration therapies. (Link)
  11. Kaiser Permanente and Renown Health complete joint venture to jointly own Hometown Health and expand integrated care access in northern Nevada
    The finalized partnership marks Kaiser Permanente’s entry into northern Nevada through the joint ownership of Hometown Health and collaboration with Renown Health’s established provider network. The venture aims to expand access to affordable, value-based care while integrating insurance coverage and clinical delivery across the region. Kaiser Permanente will open two new medical centers in 2026, adding to its existing Reno location, and plans to introduce its digital health platform and in-house pharmacy network by 2027. The collaboration combines Kaiser Permanente’s national capabilities with Renown’s strong local presence to enhance clinical outcomes and improve patient experience across northern Nevada. (Link)
  12. NuvemRx acquires 340B referral technology company par8o from R1 RCM, via its financial sponsors Parthenon Capital Partners and Rainmaker Strategic Capital to enhance specialty care coordination and expand pharmacy network capabilities
    The acquisition integrates par8o’s AI-powered referral capture technology with NuvemRx’s pharmacy management and third-party administration services, enabling covered entities to more efficiently manage 340B referrals and specialty prescriptions. The combined platform now supports over 800 covered entities and impacts more than 70 million patients nationwide. By automating up to 85% of the referral and eligibility process, the integration reduces administrative burdens, enhances compliance, and increases savings opportunities for safety-net providers. The move strengthens NuvemRx’s mission to simplify pharmacy operations, expand access to affordable care, and improve coordination across community health and specialty care networks.  (Link)
  13. MedRisk to acquire Horizon Casualty Services PPO Network business from Horizon Mutual Holdings, via its financial sponsors CVC Capital Partners and The Carlyle Group to expand managed care capabilities in workers’ compensation and auto casualty markets
    The acquisition enhances MedRisk’s reach and service offerings within the casualty claims industry by integrating Horizon Casualty Services’ PPO Network business. The move aligns with MedRisk’s strategy to deliver improved patient outcomes, streamlined claims management, and optimized payment solutions. The integration supports faster recovery times, smarter spending, and enhanced client value while reinforcing the company’s commitment to innovation and superior service across workers’ compensation and auto casualty markets. (Link)
  14. Coloplast discloses definitive agreement for Uramedica acquisition in Q1 2025/26 earnings Report
    Coloplast US signs definitive merger agreement to acquire all outstanding shares of Uromedica, a privately held US medtech company specializing in minimally invasive treatments for stress urinary incontinence, making Uromedica a wholly owned subsidiary. The acquisition is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. The move aligns with Coloplast’s strategy to bolster growth in urology through targeted additions, amid strong organic performance in the division. (Link)
  15. Konovo acquires Rare Patient Voice, via its financial sponsors Bain Capital Credit, Frazier Healthcare Partners, GV Investment Managers and Leavitt Equity Partners to expand access to 200,000+ patients and caregivers The acquisition strengthens Konovo’s healthcare intelligence platform by combining its data-driven capabilities and healthcare provider network with Rare Patient Voice’s extensive, community-driven database of patients and caregivers. This integration enhances the ability of researchers to access hard-to-reach populations and capture real-world patient insights across therapeutic areas. Konovo plans to scale these efforts globally while integrating patient and clinician perspectives into unified, technology-enabled research solutions. The partnership drives faster, more informed decision-making for healthcare organizations advancing innovation in complex diseases. (Link)
  16. RadNet (NASD: RDNT) acquires Northwest Radiology in Indiana, adding six imaging centers to expand Midwest footprint and enhance AI-powered diagnostic services
    The acquisition marks RadNet’s entry into Indiana, extending its national imaging network into the Midwest through six outpatient centers in the Indianapolis region. Northwest Radiology’s 18 radiologists will continue providing contracted professional services, ensuring continuity and maintaining strong local physician relationships. The integration will leverage RadNet’s advanced imaging technologies and AI-driven workflows to improve early disease detection and overall population health management. With the addition expected to generate approximately $18 million in annual revenue, RadNet aims to expand its proactive diagnostic approach while strengthening patient access to high-quality, cost-effective imaging care across Indiana. (Link)
  17. Nautic Partners completes growth investment in KabaFusion as Novo Holdings exits, supporting expansion of home infusion care services
    The partnership marks a new phase for KabaFusion, a national leader in home and alternate site infusion therapy. With operations covering 45 states through 33 pharmacies and 21 infusion suites, the company will leverage Nautic Partners’ investment to accelerate its growth and innovation initiatives. KabaFusion’s management team, which remains significant investors, will continue leading the organization to enhance patient access and clinical excellence. The investment underscores Nautic’s strategy of backing mission-driven healthcare providers delivering high-quality, patient-centered care, marking the exit of Novo Holdings following its successful tenure supporting KabaFusion’s nationwide expansion. (Link)
  18. Black Pearl Equities Announces Intention to Commence Tender Offer to Acquire Selectis Health, Inc.
    Black Pearl Equities, LLC announces intention to commence an all-cash tender offer to acquire all issued and outstanding shares of common stock of Selectis Health, Inc. (OTC: GBCS) at $4.00 per share. The proposed transaction is subject to negotiation and execution of definitive transaction documentation as well as customary closing conditions.  Selectis Health operates skilled nursing and transitional care facilities, and this unsolicited proposal follows the company’s recent asset sales and operational streamlining efforts. (Link)
  19. Vanderbilt Health acquires Tennova’s Clarksville Hospital, Tennova ER-Sango, and physician clinics from Community Health Systems to expand regional care network
    The acquisition expands Vanderbilt Health’s footprint across Middle Tennessee, adding the 270-bed Clarksville hospital, freestanding Sango ER, and multiple physician practices to its growing regional system. Vanderbilt Clarksville Hospital (VCH) will serve as a hub for expanded emergency, surgical, and specialty services, with new paediatric and adult programs planned in collaboration with Monroe Carell Jr. Children’s Hospital. The integration brings nearly 1,100 staff and over 30 physicians into Vanderbilt’s network, reinforcing its commitment to delivering high-quality, community-based care. The move marks Vanderbilt’s fourth regional hospital acquisition, extending its reach beyond Nashville and strengthening access to advanced health services statewide. (Link)

Venture and Other News  

  1. Midi Health closes $100M Series D in Goodwater Capital–led round with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens and McKesson Ventures to scale national women’s health platform
    The virtual women’s health clinic now serves over 230,000 patients across 50 states through a network of 500 providers, treating 25,000 patients weekly. Founded in 2021 to address perimenopause and menopause care, the company is expanding into metabolic health, weight management, and musculoskeletal health. The platform uses AI-powered tools for chart analysis, scheduling, and care protocols while offering insurance-backed services reaching 45 million women. The company reports improved screening adherence rates and up to 13% lower total cost of care, with plans to expand Medicare and Medicaid coverage. (Link)
  2. Chamber raises $60M Series A led by Frist Cressey Ventures with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures to scale cardiology value-based care
    The funding will accelerate Chamber’s mission to modernize cardiovascular care through value-based models that improve outcomes while lowering costs. The company’s platform integrates AI-driven insights to help cardiologists identify high-risk patients, close care gaps, and streamline workflows within existing systems. Partnering with both payers and practices, Chamber supports data-informed, proactive management of chronic heart disease. With more than 500 cardiologists across seven states already on its network, the company plans to expand its national footprint and strengthen partnerships with health plans. The investment underscores growing momentum behind value-based innovations addressing cardiovascular care delivery and patient experience. (Link)
  3. Alaffia Health raises $55M Series B led by Transformation Capital with FirstMark Capital, Tau Ventures, and Twine Ventures to expand AI-driven health plan operations
    The latest funding round accelerates Alaffia Health’s mission to reduce healthcare’s $570 billion in administrative waste through advanced, clinically informed AI for health plan claims management. The company’s platform combines physician oversight with agentic AI to enhance accuracy, speed reviews, and achieve measurable cost savings for national and regional payers. Delivering over 20% savings on high-cost claims and fivefold ROI, Alaffia plans to use the new capital for R&D, product innovation, and scaling adoption across the healthcare ecosystem. The investment supports ongoing efforts to create transparent, compliant, and efficient claims infrastructure that strengthens affordability and systemwide operational performance. (Link)
  4. Third Arc Bio raises $52M Series A extension led by Andreessen Horowitz with Omega Funds, Goldman Sachs Alternatives, BVF Partners, T. Rowe Price, Galapagos NV, AbbVie Ventures and Alderline Group to advance oncology and immunology pipeline
    The funding strengthens Third Arc Bio’s efforts to expand its multifunctional antibody programs in oncology and immunology. The capital will accelerate clinical development of the company’s lead asset, ARC101—a bispecific T cell engager targeting CLDN6 in advanced solid tumours—while advancing next-generation inflammation and immune modulation candidates toward human trials. Leveraging its ARCTag (Tethered Agonist) platform, Third Arc Bio aims to localize immune activity precisely at disease sites, enhancing efficacy and reducing systemic toxicity. Supported by a seasoned scientific team, the company continues to validate its platform approach to develop targeted biologics addressing major unmet medical needs. (Link)

Market Rumours

  1. Seed Health reportedly retains Centerview Partners to explore potential sale amid strong financial performance
    Seed Health has reportedly hired Centerview Partners to advise on a potential sale as it attracts strong interest from strategic and private equity buyers. Generating about $200 million in revenue and over $50 million in EBITDA, the company aims to leverage rising global demand for premium probiotics and wellness products.
  2. HHAeXchange reportedly explores sale with Centerview Partners advising; backed by Cressey & Company and Hg Capital
    The company, generating about $100 million in recurring revenue, develops software that streamlines compliance and operations for Medicaid homecare providers. Having expanded through acquisitions of Sandata Technologies, Generations Homecare Systems, and Cashe Software, it reflects growing investor interest in post‑acute healthcare tech consolidation during ongoing strategic review discussions.
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Spenser Lin No Comments

Q4 2025 Behavioral Health M&A and Investment Quarterly Newsletter

LECO_Behavioral-Market-Update-Q4_2025Download

Q4 2025 Highlights:
• Deal volume hit multi-year highs for the full year—but slowed sharply in Q4 as buyers turned cautious.
• Private capital is still flowing—but selectively, with outpatient mental health and autism platforms pulling ahead while safety-net providers fall further behind.
• Facility closures accelerated nationwide, cutting inpatient and residential capacity as Medicaid and federal funding tightened.
• Policy volatility is now an operating risk—January’s SAMHSA grant whiplash froze planning and investment for community providers.
• Telehealth survived the rollback (for behavioral health), quietly reinforcing its role as core infrastructure.
• Workforce shortages and burnout are worsening, even as demand keeps rising.

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 26th, 2026

LECO_Weekly-Healthcare-News_1-26-2026Download
  1. Winter Storm Fern Cripples Half the Country This Weekend
    • CNBC: $100B expected economic loss and damages from storm (Link) 
    • CNBC: Transportation Sec. Duffy says air travel will return to normal by Wednesday (Link) 
    • The Weather Channel: Winter Storm Fern Turns Deadly In Louisiana, Outages For Hundreds Of Thousands Vulnerable To Ice, Snow (Link) 
    • National Public Radio: As the winter storm rages, here’s what to know in your state(Link)
  2. GSK (NYSE:GSK) pays $2.2B to acquire Rapt Therapeutics (NASD:RAPT) and Food Allergy Antibody Ozureprubart GSK is acquiring Rapt Therapeutics for $58 per share, gaining global (ex‑China) rights to ozureprubart, an extended‑half‑life anti‑IgE antibody being studied as a 12‑weekly prophylactic treatment for food allergies. Unlike currently approved IgE inhibitors that require injections every 2–4 weeks, ozureprubart aims to offer sustained protection with less frequent dosing while targeting the same validated pathway as Xolair. The deal follows Rapt’s strategic pivot away from its CCR4 inhibitor program after clinical setbacks and positions ozureprubart for phase 2 readout in 2027 and a planned phase 3 program, backed by GSK’s global development and commercialization infrastructure. (Link)
  3. BioCryst (NASD: BCRX) acquires Astria Therapeutics (NASD:ATXS) in $700M deal to Build Comprehensive Hereditary Angioedema Treatment Platform The transaction adds Navenibart, a long-acting plasma kallikrein inhibitor in Phase 3, which is being developed as a prophylactic HAE treatment with every‑three or every‑six month dosing to improve patient convenience and attack control. BioCryst now pairs its existing oral therapy ORLADEYO with a potential injectable option to give clinicians more flexibility in tailoring care. The deal also brings STAR0310, an early atopic dermatitis program for which strategic options will be explored, and augments BioCryst’s leadership with Astria’s former CEO joining the board and a senior development leader taking charge of technical operations. (Link)
  4. Georgia ProtonCare Center, Inc. Files Chapter 11 to Facilitate Competitive Sale Process and Enters Into Asset Purchase Agreement With Emory Healthcare Georgia ProtonCare Center (GPCC), owner of Georgia’s only proton therapy cancer treatment facility in Midtown Atlanta, has filed for Chapter 11 bankruptcy to facilitate a court-supervised sale process and ensure uninterrupted patient care. The company has signed an asset purchase agreement with Emory Healthcare (via Emory University Hospital Midtown) as the stalking horse bidder to acquire substantially all assets, with Emory clinicians already providing daily treatment at the center. GPCC aims to complete the competitive sale by Q2 2026, prioritizing seamless continuation of precision proton therapy services for cancer patients while operations continue as usual under court-approved funding. (Link)
  5. KidsChoice Announces Majority Investment from Aquitaine Capital to Support Growth and Clinical Excellence KidsChoice, an Oklahoma-based provider of clinic-centered autism and pediatric therapy services including ABA, speech, and occupational therapy, has secured a majority investment from women-owned private equity firm Aquitaine Capital to fuel expansion, enhance clinical excellence, and strengthen infrastructure. The partnership supports thoughtful growth through new clinic openings, strategic M&A, and complementary offerings while prioritizing individualized, outcomes-driven care for children and families. (Link)
  6. Community Health Systems Sells Crestwood Medical Center to Huntsville Hospital Health System in $450M Deal The transaction will transfer Crestwood Medical Center, a 180‑bed acute care hospital in Huntsville, Alabama, along with a freestanding emergency department in Harvest and multiple clinics and outpatient assets, to a regional nonprofit operator. Crestwood’s roughly 1,000 employees will continue normal operations with no planned changes to services or medical staff privileges during the transition. Huntsville Hospital Health System, already a major 14‑hospital network across northern Alabama and southern Tennessee, views the deal as a way to better coordinate local care as Huntsville’s population rapidly grows, while the seller continues its strategy of divesting assets to strengthen its financial position. (Link)
  7. BioStem Technologies (OTC: BSEM) and BioTissue sign Up to $40M Surgical and Wound Care Asset DealThe transaction adds BioTissue’s Neox and Clarix placental- and umbilical‑tissue allograft product lines, along with a national direct and independent sales force and key group purchasing organization contracts, giving BioStem an immediate presence in hospital inpatient and outpatient settings. The acquired surgical and wound care assets, which generated about $29 million in 2025 sales, broaden BioStem’s chronic and acute wound care portfolio and create entry into high‑value segments such as burns and soft‑tissue repair. Deal terms include an upfront $15 million cash payment plus up to $25 million in potential regulatory and commercial milestone payments. (Link)
  8. Harmony Healthcare IT acquires Blue Elm, via its financial sponsor Novacap to build Comprehensive MEDITECH Data Lifecycle Platform Harmony Healthcare IT has acquired Blue Elm to offer MEDITECH hospitals a single, end-to-end partner for data extraction, conversion, migration, archiving, optimization, and real-time access across all MEDITECH versions. The combined capabilities help hospitals retire costly legacy systems, strengthen data integrity, and improve accessibility as they upgrade or transition EHR platforms. By unifying services under one organization and relying on U.S.-based resources instead of offshore outsourcing, the company aims to shorten complex project timelines, enhance security and quality, and better support hospitals under pressure to improve care quality while reducing operating costs. (Link)
  9. PhaseWell Research acquires Bio Behavioral Health Partner, via its financial sponsor Shore Capital Partners to expand Community-Based Neuropsychiatric Clinical Trials The acquisition will strengthen PhaseWell’s national network of community clinical research sites focused on neurologic and psychiatric disorders. The collaboration aims to broaden patient access to neuropsychiatric trials by leveraging BBH’s experience in community-based studies and PhaseWell’s nationwide platform and infrastructure. Together, the organizations plan to support sponsors with reliable patient enrolment, strong operational execution, and high-quality data while advancing next-generation CNS therapeutics across complex therapeutic areas, including oncology, cardiovascular/metabolic conditions, and dermatology. (Link)
  10. Pair Team acquires Town Square to Advance AI-Enabled Community Care for Medicare and Medicaid Beneficiaries The acquisition combines an AI-driven medical group with a social care coordination platform to better integrate clinical, behavioral, and social services for underserved populations. Technology will orchestrate complex, cross-setting care tasks so human teams can concentrate on clinical decisions, hands-on support, and relationships with patients and local organizations. Town Square’s founder will lead network expansion and community partnerships within the new structure, which emphasizes responsible AI, robust outcomes measurement, and investment in community-based infrastructure to extend whole-person care to people historically excluded from the healthcare system. (Link)
  11. Aspen Surgical expands Infection Prevention Portfolio with acquisition of Ruhof Healthcare, via its financial sponsors Linden and Audax Private Equity The buyer is adding enzymatic detergents, cleaning verification tools, and automated and manual instrument and endoscope reprocessing solutions to deepen its presence in operating rooms, sterile processing, and endoscopy settings. Ruhof’s portfolio, including Endozime detergents, ScopeValet single-use consumables, CleanRead ATP contamination monitoring, and instrument refurbishment services, will bolster the SPD360 Performance Solutions platform and complement existing brands such as Symmetry, Bookwalter, and Precept. The transaction covers all Ruhof operations, brands, and product lines, with integration set to begin immediately and no near-term disruption expected for customers, suppliers, or employees. (Link)
  12. TridentCare acquires DispatchHealth Imaging Unit to Grow National Portable Diagnostics Network The acquisition adds a multistate mobile X‑ray and ultrasound operation that serves patients at home, in post‑acute facilities, and in correctional settings, expanding TridentCare’s reach and capacity. By integrating these imaging teams and customers into its national infrastructure, TridentCare aims to speed response times, improve scheduling flexibility, and deliver more consistent service quality for clinicians and patients. DispatchHealth will continue focusing on providing complex care in the home and will coordinate imaging through technology and partnerships so patients and providers experience seamless, integrated services. (Link)
  13. Morris & Dickson Completes Transaction to Acquire Prodigy Health Morris & Dickson (M&D), the nation’s largest independent wholesale and specialty pharmaceutical distributor, has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company focused on plasma-derived therapies. The transaction expands M&D’s specialty portfolio, broadens access to plasma therapies for hospitals, clinics, infusion centers, and alternative care sites nationwide, and strengthens its independent platform for manufacturers through a compliance-first approach. (Link)
  14. Main Post Partners and HomeWell Leadership acquire HomeWell Franchising to Accelerate Senior In‑Home Care Growth The deal pairs a national non‑medical home care franchisor with a private equity firm experienced in franchising and consumer service brands, aiming to fuel the next phase of expansion. The partners emphasize a “partnership, not ownership” philosophy, focusing on close collaboration with franchisees and caregivers to scale services while preserving mission and culture. Building on several years of rapid revenue growth and record franchise development, the company plans to invest in tools, resources, and support that help local agencies grow and better serve seniors and homebound individuals in their communities. (Link)

Venture and Other News  

  1. Zarminali Paediatrics raises $110M in Series A funding led by Healthier Capital, with participation from General Catalyst, K2 HealthVentures, and Boston Children’s Hospital to expand integrated paediatric care footprint The company will use the new capital to scale its proprietary tech platform, enter additional states and open de novo clinics while continuing to acquire established paediatric groups. Its model centers on a single branded multispecialty practice that co-locates clinics with urgent care, directly employing both paediatricians and specialists to coordinate care across the full continuum outside the hospital. Since launching in 2024, Zarminali has rapidly expanded to 28 clinics in eight states and plans at least 15 new sites in 2026, while laying groundwork for future value-based arrangements and building analytics to track clinician performance and patient outcomes. (Link)
  2. Mendra launches with $82M Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC to advance AI-driven rare disease therapeutics Mendra will use the oversubscribed financing to acquire and develop an initial portfolio of high-potential rare disease assets while applying AI to speed patient identification, trial enrollment and global market access. The company is built to modernize how rare disease medicines are developed and commercialized so they reach underserved patients more efficiently worldwide. A veteran leadership team with deep experience in rare disease drug development, global commercialization and AI—drawn from organizations such as BioMarin, Modis Therapeutics, Escient Pharmaceuticals, Palantir and Bayer—will guide strategy across asset selection, clinical execution and business development. (Link)
  3. AnswersNow raises $40M in Series B funding led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to Scale AI-Enabled Virtual Autism Therapy The company will use the new capital to expand its platform, double clinical headcount, add senior leaders and launch new service lines to meet surging demand for autism support. Its AI-driven model pairs families across the U.S. with Master’s- and PhD-level BCBAs for targeted, parent-mediated virtual ABA, cutting weekly therapy time from 30+ hours to about 4–5 while sustaining strong clinical gains. Outcomes data show high family-reported improvements, substantial cost savings for payors and a consistently strong satisfaction score, with forthcoming research in 2026 intended to further validate clinical and economic impact. (Link)
  4. BrightInsight secures $13M investment from Eclipse, General Catalyst, Insight Partners, Mayo Clinic and New Leaf Venture Partners to scale its AI-enabled medication adherence platform The company will deploy the capital to expand its AI-enabled persistence and adherence solutions, including a co-developed Patient App used across multiple diseases and therapies worldwide. By leveraging real-world data and advanced analytics, the platform targets chronically low adherence rates, aiming to predict churn and trigger personalized interventions that keep patients on therapy. BrightInsight reports strong patient engagement and one-year retention across programs and plans to deepen its product roadmap, broaden disease and biopharma partnerships, and add support for caregivers and nurse educators to ease pressure on health systems. (Link)
  5. McKinsey & Co Released their Annual Healthcare Outlook Report. To remain competitive in 2026 and beyond, healthcare leaders must improve performance, embrace technology and rethink traditional care models (Link)
  6. IPO Watchlist
    • Once Upon a Farm — Organic children’s food company co-founded by Jennifer Garner, is targeting a valuation of up to $764.4 million in its upcoming U.S. IPO on the NYSE under the ticker OFRM. (Link)
    • Kallyope — New York City-based biotechnology company specializing in novel therapeutics targeting the gut-brain axis and neural circuits.
    • Kardium — Vancouver area based medical device company focused on cardiac electrophysiology solutions; develops advanced catheter-based systems for the diagnosis and minimally invasive treatment of atrial fibrillation.
    • Tenpoint Therapeutics — London, UK-headquartered (with U.S. operations in Seattle and Irvine) ophthalmic biotechnology company dedicated to age-related vision restoration therapies.
    • Vensure Employer Solutions — Chandler, AZ -based professional employer organization (PEO) and provider of human capital management (HCM) technology serving the healthcare and broader employer ecosystem.
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 20th, 2026

LECO_Weekly-Healthcare-News_1-20-2026-1Download

Healthcare Weekly News and Deals – January 20th, 2026

  1. Takeaways from JPM 44th Annual Healthcare Conference 2026 The J.P. Morgan Healthcare Conference 2026 reflected a turn toward cautious yet genuineoptimism, fueled by policy tailwinds, AI’s proven impacts, and robust activity in strategiccollaborations and consolidations. AI emerged as a core driver, transitioning from hype tooperational ROI via agentic systems, closed-loop workflows, and ambient tools that enhancediscovery, delivery, and administrative efficiency. Federal efforts, including outreach on quality andaccess alongside high-impact innovation programs, underscore a proactive stance on reducingbarriers and accelerating progress. Cross-border dynamics and emerging modalities added to theforward-looking tone, signaling diversified growth opportunities. The event highlightedhealthcare’s trajectory for AI-enabled reinvention, with widespread alignment on prioritizingefficiency, transparency, execution, and adaptive strategies to navigate global and regulatory shifts.
    ● PitchBook Analyst Note: Takeaways from the J.P. Morgan Healthcare Conference (Link)
  2. OpenAI acquires Torch in ~$100M deal to accelerate ChatGPT Health OpenAI bought healthcare startup Torch, which aggregates users’ lab results, medications, visit notes, wearable data and consumer test reports into a unified health record, and will fold its team into efforts to expand ChatGPT Health. The year‑old Torch platform was built as a “medical memory” to unify fragmented records into a single context layer for AI. The acquisition follows OpenAI’s launch of ChatGPT Health, which links the chatbot to medical records and wellness apps for more personalized responses. OpenAI reports that about one in four of ChatGPT’s 800 million regular users asks at least one healthcare‑related question each week. (Link)
  3. Boston Scientific (NYSE: BSX) to acquire Penumbra (NYSE: PEN) in $14.5B cash-and-stock deal to expand vascular and neurovascular portfolio The transaction will be paid approximately 73% in cash and 27% in Boston Scientific stock, giving Penumbra shareholders the option of cash or shares subject to proration. Penumbra brings a portfolio that includes Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy systems, peripheral embolization solutions, and neurovascular devices for stroke, aneurysms and other complex vascular conditions. Boston Scientific plans to fund the roughly $11 billion cash component with a mix of cash on hand and new debt and currently expects the deal to be modestly dilutive to adjusted earnings per share in the first full year after closing, turning neutral to accretive thereafter. (Link)
  4. Smith+Nephew (NYSE: SNN) to acquire Integrity Orthopaedics in Deal Worth up to $450M to Strengthen Rotator Cuff Portfolio The transaction includes an upfront $225 million cash payment plus up to $225 million in performance-based milestones over five years and is expected to close this month. Integrity Orthopaedics’ Tendon Seam rotator cuff repair system is designed with patented micro-anchors, individually locked stitches and an integrated implantation system to reduce re-tear rates and shorten procedures compared with traditional techniques, which can have structural failure rates of 20–40%. The acquisition supports Smith+Nephew’s RISE 2026 strategy and builds on prior shoulder investments, including the Regeneten bioinductive implant, Q-Fix Knotless All-Suture Anchor and the Aetos Shoulder System. (Link)
  5. Modella AI acquired by AstraZeneca (LON: AZN) to scale AI-driven oncology R&D globally The acquisition expands a multi-year collaboration by embedding Modella AI’s multimodal foundation models and agentic AI platform directly into AstraZeneca’s oncology research and development ecosystem. Modella AI’s technology, built at the intersection of pathology, clinical data and advanced generative AI, will be used to accelerate clinical development, enhance biomarker discovery and support data‑driven decision-making across AstraZeneca’s global oncology portfolio. AstraZeneca plans to deploy these AI agents and pathology foundation models to increase automation, scalability and consistency in data‑intensive workflows and to support the development of targeted therapeutics and companion diagnostics. (Link)
  6. Boston Scientific (NYSE: BSX) acquires Valencia Technologies to add eCoin ITNS device to urology portfolio The eCoin implantable tibial nerve stimulation system, placed under the skin near the ankle, is intended for urge urinary incontinence patients who do not tolerate or sufficiently benefit from conservative therapies, and received FDA clearance in 2022. In a pivotal study, 68% of treated patients achieved at least a 50% reduction in UUI episodes, underscoring its potential clinical impact. The transaction is expected to close in the first half of 2026, positioning Boston Scientific alongside Medtronic’s Altaviva device in the growing neuromodulation market for overactive bladder–related symptoms as the company continues to expand its pelvic health and neurology device franchises. (Link)
  7. Abbott (NYSE: ABT) and AtaCor collaborate on Next-Generation Extravascular ICD System The partners are combining an investigational parasternal extravascular defibrillation lead (Atala) with a minimally invasive implantable defibrillator platform intended to keep hardware outside the heart and vasculature, aiming to avoid complications such as vascular injury, lead fracture and infections. The Atala lead is placed through a rib space beside the sternum and is designed both to deliver defibrillation shocks and to direct pacing energy efficiently toward the heart. A pivotal ALARION EV Investigational Device Exemption study is planned for 2026 to evaluate the system as a potential new option for patients at high risk of life‑threatening arrhythmias. (Link)
  8. Hippocratic AI acquires Grove AI to build end-to-end agentic AI platform for biopharma and medtech The acquisition adds Grove AI’s agentic platform, which has supported over 10 million patient interactions and powered more than 50 phase 2 and 3 clinical trials, into Hippocratic AI’s life sciences division focused on regulated biopharma and MedTech use cases. Grove’s “Grace” agent and participant relationship management tools will be used to speed recruitment, improve screening and streamline trial operations across top global pharma partners, while Hippocratic extends agents into commercial, direct‑to‑patient and HCP engagement. The company has appointed Ahad Wahid, M.D., as president of life sciences and formed a senior advisory council to ensure safety, compliance and large‑scale deployment. (Link)
  9. Agentis Longevity acquires Arete Wellness, via its financial sponsor Shore Capital Partners to build national precision longevity and recovery platform The combined company will offer personalized, preventative programs that integrate advanced diagnostics, hormone and peptide therapies, IV recovery, performance medicine and lifestyle-focused support for high-performing clients such as professional athletes, entertainers and executives. Arete contributes a concierge recovery model delivered by a team of more than 45 traveling nurses and medical professionals, while Agentis brings precision-based longevity medicine focused on individualized, science-backed care. Leadership from both organizations position the deal as a way to expand geographic reach, increase accessibility and set a new standard for evidence-based performance longevity without disclosing financial terms. (Link)
  10. Apollo Care acquires eStrat, via its financial sponsor Flexpoint Ford to expand copay and patient access capabilities Apollo Care is adding eStrat’s copay program design and execution expertise to strengthen its technology-driven patient access, affordability and analytics platform. The combined offering aims to enable faster copay program launches, tighter integration between operations and analytics, and more seamless execution for pharmaceutical manufacturers across multiple therapeutic areas. Key eStrat team members are joining Apollo Care to ensure continuity for existing clients, with co-founder Trond Waerness stepping into a leadership role focused on patient affordability strategy. The companies say the deal will help manufacturers reduce complexity while improving access and affordability for patients. (Link)
  11. Zelis acquires Rivet, via its financial sponsors Bain Capital, Parthenon Capital Partners, Valspring Capital, BPEA Private Equity, Edison Partners, Bain Capital Ventures, Norwest, Ergo Partners, HarbourVest Partners and Mubadala Investment Company, to expand AI‑enabled revenue cycle analytics for healthcare payers and providers The deal adds Rivet’s analytics platform to Zelis’ existing payments technology, giving providers deeper visibility into claim payment patterns and denial trends via insight‑rich dashboards and workflow tools. By reducing transactional back‑and‑forth, payers can shift focus to collaborative efforts that improve first‑time claim success and cut down on costly rework. Executives from both companies frame the combination as a way to address mounting margin pressure, rising administrative costs and regulatory complexity while pushing the industry toward a more transparent, efficient financial experience for providers, payers and patients. (Link)
  12. Genomate Health acquires Oncompass Medicine to build integrated precision oncology platform in Europe The deal gives Genomate Health a long-standing European base with established logistics, clinical operations and market presence in personalized oncology, particularly in Hungary and across Europe. Oncompass, founded in 2003, brings two decades of experience in companion diagnostics and next-generation sequencing-based tumour profiling in routine clinical care. Scientific and clinical leadership will be driven by Genomate Health Founder and CSO Istvan Petak, who will also serve as Managing Director of Oncompass Medicine, as the combined organization deploys Genomate’s computational reasoning technology to turn complex molecular data into scalable, actionable treatment decisions for cancer patients worldwide. (Link)
  13. Behavioral Framework partners with Autism ETC, backed by Renovus Capital Partners, to expand autism care platform Autism ETC, which operates five ABA therapy and autism diagnostic clinics in Tennessee and Arizona, will join Behavioral Framework while retaining its leadership team and clinical staff to ensure continuity for families and employees. The combination is intended to extend high-quality, individualized autism services across both center-based and home-based models in the Southeast and beyond, supported by Behavioral Framework’s operational infrastructure, technology and growth resources. Both organizations emphasize preserving Autism ETC’s culture and clinical integrity while scaling access and investing in clinician development as part of Behavioral Framework’s broader growth strategy. (Link)
  14. EnableComp acquires Health Resources Optimization via its financial sponsors Primus Capital and Welsh, Carson, Anderson & Stowe to expand complex revenue recovery for hospitals The acquisition brings H/ROI’s clinical denials and post‑bill DRG validation expertise under EnableComp, strengthening its focus on complex claims, DRG downgrades and medical‑necessity denials. The combined organization aims to capture more hidden revenue for providers facing intense margin pressure and payer scrutiny by pairing seasoned clinical judgment with an AI‑driven revenue cycle platform. Serving over 1,000 hospitals and recovering $3 billion annually, EnableComp is integrating H/ROI to deliver deeper clinical insights, earlier underpayment detection and faster resolution of intricate denials so health systems can safeguard margins and improve financial stability while maintaining patient care. (Link)
  15. Solis Mammography acquires Women’s Center for Radiology, via its financial sponsors Madison Dearborn Partners and TowerBrook Capital Partners to expand Florida breast imaging footprint The deal adds two Orlando centers to Solis Mammography’s existing nine Florida locations in Gainesville, Fort Lauderdale and Miami, marking the company’s entry into the Orlando market and broadening its statewide presence in specialized breast health services. The combined organization aims to deliver comfortable, convenient and compassionate breast imaging to more patients across greater Florida while maintaining personalized, community-focused care. (Link)

Venture and Other News   

  1. JPM26: Anthropic launches Claude for Healthcare to Turbocharge AI efficiency at HealthSystems, Payers Anthropic introduced Claude for Healthcare at the J.P. Morgan Healthcare Conference (JPM26), providing purpose-built, HIPAA-ready AI tools for health systems, payers, providers, and hospitals to accelerate administrative and clinical workflows including prior authorization, clinical documentation, claims management, care coordination, regulatory submissions, and patient message triage. The platform connects Claude to key data sources such as the CMS Coverage Database (Local and National Coverage Determinations), ICD-10 codes, National Provider Identifier Registry, and PubMed (with over 35 million biomedical literature entries), enabling natural language querying, surfacing coverage differences, reducing claim denials, and supporting FHIR interoperability via Agent Skills. It builds on the October launch of Claude for Life Sciences with additional connectors for platforms like Medidata and ClinicalTrials.gov, while offering consumer-facing features like medical history summarization and health metric pattern detection through beta integrations with HealthEx, Function, Apple Health, and Android Health Connect. Emphasizing AI safety through its Constitutional AI approach, the tools aim to minimize hallucinations, ensure reproducible and cited results, and amplify human capabilities in highstakes, regulated healthcare environments, with early adoption by organizations including Banner Health, Stanford Healthcare, Novo Nordisk, Sanofi, AbbVie, and Genmab. (Link)
  2. OpenAI Invests in Merge Labs’ $250M Seed Led by OpenAI with Bain Capital, Interface Fund, Fifty Years and Gabe Newell to Advance Noninvasive Brain‑Computer Interfaces Merge Labs, a brain-computer interface “research lab” co-founded by Sam Altman and collaborators from Tools for Humanity, Forest Neurotech and Caltech, raised $250 million at an $850 million valuation to pursue non-invasive BCIs that link biological and artificial intelligence using molecules and deep-reaching modalities like ultrasound. The startup aims to extend human capabilities and restore or enhance brain function by interfacing with neurons at scale, with applications well beyond current medical BCI use cases. OpenAI plans to collaborate with Merge on foundation models and AI operating systems that interpret neural intent and work robustly with limited, noisy brain signals. (Link)
  3. Proxima raises $80M Seed Led by DCVC with NVentures, Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments and Modi Ventures to Advance Proximity-Based Medicines The AI-native biotech, formerly VantAI, is developing proximity therapeutics that modulate protein–protein interactions, including modalities like molecular glues and PROTACs, to reach historically “undruggable” targets across oncology, immunology and other diseases. Its NeoLink data-generation technology and Neo AI model series generate proteome-scale structural data on protein complexes to enable rational design of proximity-modulating small molecules, with aims to improve safety and shorten development timelines. The company has secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb and Blueprint Medicines, with multiple partnered programs progressing toward the clinic and the first expected to enter trials in 2026. (Link)
  4. Vista AI raises $29.5M series B with Cedars-Sinai Health System, Intermountain Health, University of Utah Hospital System, Temple University/Fox Chase Cancer Center, Tampa General Hospital, Khosla Ventures and Bold Brain Capital to Expand Automated MRI Imaging Platform The company’s AI software automates MRI scanning workflows to reduce complexity and variability, helping radiology teams keep up with rising MRI demand amid technologist shortages. Vista AI plans to expand from its FDA-cleared cardiac MRI platform into brain, prostate and spine imaging and add remote scanning services so sites without in-house expertise can offer advanced exams. Early adopters such as Brigham and Women’s Hospital and Radiology Regional report 50% more cardiac MRI slots, elimination of a 28-day backlog, and scan times cut by more than half without adding staff or scanners. (Link)
  5. Converge Bio raises $25M Series A Led by Bessemer Venture Partners with TLV Partners, Saras Capital, Vintage Investment Partners and Executives from Meta, OpenAI and Wiz to Accelerate AI-Driven Drug Discovery The Boston- and Tel Aviv-based startup builds generative AI models trained on DNA, RNA and protein sequences to plug directly into pharma and biotech workflows across target discovery, antibody design, protein yield optimization and biomarker discovery. Its customer-facing systems integrate generative, predictive and physics-based docking models so clients receive ready-to-use platforms rather than stitching tools together. In two years, Converge has completed more than 40 programs with over a dozen customers across the U.S., Canada, Europe and Israel, reporting up to 4–4.5X protein yield gains and single‑nanomolar affinity antibodies, and is now expanding into Asia. (Link)